According to a recent LinkedIn post from SeqOne, the company recently participated in a workshop in Lisbon focused on helping Hospital de Santa Maria build an in-house clinical next-generation sequencing, or NGS, facility. The event, organized by distributor Soquimica, brought together PacBio, Agilent Technologies, and SeqOne to cover the full workflow from biological sample to clinical report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that PacBio addressed long-read versus short-read sequencing and argued for standardizing long-read technologies in routine diagnostics, while Agilent focused on sample quality control and accurate variant detection as key foundations for downstream analysis. SeqOne’s role was described as converting sequencing data into structured clinical reports across germline, oncology, and infectious disease applications.
Discussion at the workshop was portrayed as highly technical and centered on how to scale NGS rather than whether to adopt it, suggesting growing maturity and demand for advanced genomic diagnostics in hospital settings. For SeqOne, positioning its software in a collaborative ecosystem with major hardware and reagent providers could support deeper integration into clinical workflows, potentially expanding its addressable market and reinforcing its role in clinical genomics value chains.
If Hospital de Santa Maria and similar institutions successfully bring diagnostics in-house using such integrated solutions, this could drive recurring usage of SeqOne’s reporting platform tied to patient testing volumes. While the post does not disclose commercial terms or contracts, the focus on scaling and in-house adoption indicates potential for future revenue growth and broader European hospital penetration if these collaborations progress beyond the workshop stage.